Better Buy: Celldex Therapeutics, Inc. vs. Exelixis
Two oncology-focused biotech stocks began 2016 with a dip but have diverged a great deal ever since. A successful label expansion made Exelixis, Inc. Should investors try to ride the Exelixis rocket even higher, or look for value in Celldex's burgeoning pipeline? Let's see how these two stack up to each other to find the better pick right now.
from Biotech News